Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Lundbeck discovers novel PDE9 inhibitors

Jan. 26, 2017

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Jan. 24, 2017

Roche divulges novel DDR1 inhibitors

Jan. 20, 2017

Chongqing University reports PDE5A inhibitors

Jan. 13, 2017

Kissei Pharmaceutical describes TRPM8 antagonists

Jan. 12, 2017

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Jan. 5, 2017

Ardelyx initiates two new trials of RDX-7675 for hyperkalemia

Jan. 5, 2017

Vifor Pharma and ChemoCentryx expand kidney health alliance

Dec. 23, 2016

CFDA grants approval for clinical trials of fadanafil

Dec. 16, 2016

Third Rock Ventures launches Goldfinch Bio with a focus on therapies for kidney disease

Dec. 15, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.